Multiple Sclerosis Trials
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
FDA Gives Accelerated Approval to New ALS Treatment
Dr. Weisman participates in FDA Advisory Committee
ANA administers first lecanemab infusion in PA
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Dr. Weisman Quoted in NY Times Article on Aducanumab
Aducanumab: Neither Far Nor Deep
Alzheimer’s Disease: Mystery No More
Dr. Weisman interviewed on Senior Advocates, Who’s Who
Statement of inclusion
Abington Neurological Associates is proud to offer clinical trials investigating potential treatments in AD. Alzheimer’s is a terrible, fatal disease, which currently has no disease modifying treatment, and affects people of all creeds, nationalities and ethnicities. We welcome any individual with Alzheimer’s disease into these trials and will continue to do so. In previous trials, we are pleased to have contributed data from traditionally under-diagnosed and under-studied minority populations. ANA is committed to recruiting subjects until AD is cured.
Joining a trial is a highly personal decision. Aside from long lists of exclusion criteria, trials are not the right fit for everyone or for every family. Culture does play a role in this decision making. We aim to remove the barriers we can.